Drug Shortage Report for ZITHROMAX - PWS ORL 100MG/5ML
Report ID | 176316 |
Drug Identification Number | 02223716 |
Brand name | ZITHROMAX - PWS ORL 100MG/5ML |
Common or Proper name | ZITHROMAX |
Company Name | PFIZER CANADA ULC |
Market Status | MARKETED |
Active Ingredient(s) | AZITHROMYCIN |
Strength(s) | 100MG |
Dosage form(s) | POWDER FOR SUSPENSION |
Route of administration | ORAL ORAL |
Packaging size | 15mL |
ATC code | J01FA |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2023-01-29 |
Actual start date | |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2023-01-30 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2023-01-30 | English | Compare |
v2 | 2022-11-29 | French | Compare |
v1 | 2022-11-29 | English | Compare |
Showing 1 to 3 of 3